- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04222543
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging (PIVOT)
January 6, 2020 updated by: Radboud University Medical Center
Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake.
However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing.
It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy.
The exact mechanisms underlying these differences is not yet known but might be caused by changes in vascularity.
Therefore the vasculature is imaged with the help of a study specific Gallium-68-DOTA-(RGD)2 PET/CT scan and a CT perfusion scan.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The incidence of Human Papilloma Virus positive (HPV+) oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC) is rising and it has become evident that this type of cancer represents a subgroup of HNSCC that is characterized by a more favourable prognosis, mediated by a distinct tumour microenvironment, compared to patients with HPV negative (HPV-) tumours.
However, the exact mechanisms underlying this improved treatment outcome and the potential role of the tumour microenvironment are not fully understood yet.
Imaging of αvβ3 integrin expression will obtain more insight in the differences in tumour microenvironment between HPV+ and HPV- oropharyngeal HNSCC.
CT perfusion provides additional characterisation of this tumour microenvironment.
Therefore, these techniques may have the potential to predict response to treatment and might possibly steer treatment decisions in future clinical trials.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: E Aarntzen, MD, PhD
- Phone Number: +31243614048
- Email: Erik.Aarntzen@radboudumc.nl
Study Contact Backup
- Name: D Lobeek
- Phone Number: +31243614048
- Email: Erik.Aarntzen@radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands
- Recruiting
- Radboudumc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Proven squamous cell carcinoma of the oropharynx
- p-16 immunohistochemistry analysis
- Tumour lesion of at least 1.0 cm in diameter
- Planned chemoradiotherapy as primary treatment
- Ability to provide written informed consent
Exclusion Criteria:
- Contra-indications for PET
- Contra-indications for administration of iodine-containing contrast agents
- Other serious illness that can affect the scans
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: HPV Negative tumours
Patients will receive four scans.
|
Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
Other Names:
|
Active Comparator: HPV positive tumours
Patients will receive four scans.
|
Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in RGD-tracer uptake between HPV positive and negative tumours
Time Frame: 1 month
|
standardized uptake values (SUV) of Ga68-RGD
|
1 month
|
Differences in RGD-tracer uptake between the pre- and per-treatment scan
Time Frame: 1 month
|
standardized uptake values (SUV) of Ga68-RGD
|
1 month
|
Differences in CT perfusion flow parameters between HPV positive and negative tumours
Time Frame: 1 month
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
Differences in CT perfusion parameters between HPV positive and negative tumours
Time Frame: 1 month
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
Differences in CT perfusion flow parameters between the pre- and per-treatment scan
Time Frame: 1 month
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
Differences in CT perfusion parameters between the pre- and per-treatment scan
Time Frame: 1 month
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in RGD-tracer uptake between patients with locoregional control or recurrence within one year
Time Frame: 1 year
|
standardized uptake values (SUV) of Ga68-RGD
|
1 year
|
Differences in CT perfusion flow parameters between patients with locoregional control or recurrence within one year
Time Frame: 1 year
|
Determining the blood flow using ROIs of the tumour drawn on the contrast enhanced CT
|
1 year
|
Differences in CT perfusion parameters between patients with locoregional control or recurrence within one year
Time Frame: 1 year
|
Determining the blood volume using ROIs of the tumour drawn on the contrast enhanced CT
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2019
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
November 20, 2019
First Submitted That Met QC Criteria
January 6, 2020
First Posted (Actual)
January 10, 2020
Study Record Updates
Last Update Posted (Actual)
January 10, 2020
Last Update Submitted That Met QC Criteria
January 6, 2020
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL69928.091.19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharyngeal Squamous Cell Carcinoma
-
University of ArizonaNational Cancer Institute (NCI)TerminatedHPV Positive Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | CDKN2A-p16 Positive | Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 | Stage II Oropharyngeal Squamous Cell Carcinoma...United States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingTongue Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell CarcinomaUnited States, Canada, Saudi Arabia, Ireland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHuman Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Active, not recruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7United States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedPain | Dysphagia | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell CarcinomaUnited States
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
-
Washington University School of MedicineActive, not recruitingHPV Related Oropharyngeal Squamous Cell CarcinomaUnited States
Clinical Trials on RGD PET/CT
-
Radboud University Medical CenterCompleted
-
Balaji TamarappooCompleted
-
University of Lausanne HospitalsSwiss Heart FoundationRecruitingInflammation | Carotid Artery Diseases | Atheromatous PlaquesSwitzerland
-
University of Lausanne HospitalsRecruitingMyocardial Infarction, Acute | Chronic Ischemic Heart Disease | Myocardial ReperfusionSwitzerland
-
Siemens Molecular ImagingTerminatedCarotid StenosisUnited States
-
University of Lausanne HospitalsGeorge Coukos, MD PhD, Head of oncologyRecruiting
-
The First Affiliated Hospital of Xiamen UniversityCompletedPositron-Emission Tomography | Tumor, SolidChina
-
Centre Francois BaclesseCompletedMetastasis | Non-seminomatous Germ Cell TumorsFrance
-
Centre Henri BecquerelUnknown
-
Turku University HospitalUniversity of Lausanne Hospitals; Leiden University Medical CenterRecruitingCoronary Artery DiseaseFinland, Netherlands, Switzerland